Trial site
Institut Catala De Retina S.L.
Barcelona, 8022, SpainNot linked to an institution yet
- 12running trials
- 4closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 2/35 trials
- Phase 24 trials
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Completed4 trials
- Not yet recruiting2 trials
- Lead sponsor
- Eyebiotech Limited2 trials
- Janssen Research & Development, LLC2 trials
- 4d Molecular Therapeutics Inc.1 trial
- ADARx Pharmaceuticals, Inc.1 trial
- Alexion Pharmaceuticals Inc.1 trial
- and 9 more
Running trials
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
NCT07705607· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· Phase 2/3· Eyebiotech Limited· Source
Active, not recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269· Phase 2· ADARx Pharmaceuticals, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Recruiting
A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy
2023-505791-30-01· Phase 2/3· Bcn Peptides S.A.· Source
Recruiting
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
NCT05710198· Phase 3· Omikron Italia S.r.l.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error